BRPI0814457A2 - Derivados de imidazolona, composições farmacêuticas, utilização de derivados de imidazolona, e, processo de síntese de derivados de imidazolona - Google Patents

Derivados de imidazolona, composições farmacêuticas, utilização de derivados de imidazolona, e, processo de síntese de derivados de imidazolona

Info

Publication number
BRPI0814457A2
BRPI0814457A2 BRPI0814457-5A2A BRPI0814457A BRPI0814457A2 BR PI0814457 A2 BRPI0814457 A2 BR PI0814457A2 BR PI0814457 A BRPI0814457 A BR PI0814457A BR PI0814457 A2 BRPI0814457 A2 BR PI0814457A2
Authority
BR
Brazil
Prior art keywords
imidazolone derivatives
immedazolone
pharmaceutical compositions
synthesis process
derivative synthesis
Prior art date
Application number
BRPI0814457-5A2A
Other languages
English (en)
Portuguese (pt)
Inventor
Francois Carreaux
Jean-Pierre Bazureau
Steven Renault
Laurent Meijer
Olivier Lozach
Original Assignee
Univ Rennes
Centre Nat Rech Scient
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Rennes, Centre Nat Rech Scient filed Critical Univ Rennes
Publication of BRPI0814457A2 publication Critical patent/BRPI0814457A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/96—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
BRPI0814457-5A2A 2007-08-01 2008-08-01 Derivados de imidazolona, composições farmacêuticas, utilização de derivados de imidazolona, e, processo de síntese de derivados de imidazolona BRPI0814457A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0705632A FR2919608B1 (fr) 2007-08-01 2007-08-01 Derives d'imidazolones,procede de preparation et applications biologiques
PCT/FR2008/001152 WO2009050352A2 (fr) 2007-08-01 2008-08-01 Derives d'imidazolones, procede de preparation et applications biologiques

Publications (1)

Publication Number Publication Date
BRPI0814457A2 true BRPI0814457A2 (pt) 2015-01-06

Family

ID=39323606

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0814457-5A2A BRPI0814457A2 (pt) 2007-08-01 2008-08-01 Derivados de imidazolona, composições farmacêuticas, utilização de derivados de imidazolona, e, processo de síntese de derivados de imidazolona

Country Status (12)

Country Link
US (1) US8563588B2 (enExample)
EP (1) EP2185547B1 (enExample)
JP (1) JP5926885B2 (enExample)
KR (1) KR20100051698A (enExample)
CN (1) CN101784542B (enExample)
BR (1) BRPI0814457A2 (enExample)
CA (1) CA2694377A1 (enExample)
ES (1) ES2644087T3 (enExample)
FR (1) FR2919608B1 (enExample)
MX (1) MX2010001170A (enExample)
RU (1) RU2491283C2 (enExample)
WO (1) WO2009050352A2 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10316000B2 (en) 2009-02-18 2019-06-11 Cornell University Coupled recognition/detection system for in vivo and in vitro use
EP2281824A1 (en) 2009-08-07 2011-02-09 Noscira, S.A. Furan-imidazolone derivatives, for the treatment of cognitive, neurodegenerative or neuronal diseases or disorders
US11453646B2 (en) 2011-07-27 2022-09-27 Cornell University Methods for RNA detection and quantification
JP5910976B2 (ja) * 2012-07-30 2016-04-27 国立大学法人京都大学 精神神経疾患又は悪性腫瘍に関する化合物及び医薬組成物
FR3002044A1 (fr) * 2013-02-08 2014-08-15 Centre Nat Rech Scient Marqueur dyrk1a pour la maladie d'alzheimer
CN106061258A (zh) * 2013-08-29 2016-10-26 弗吉尼亚联邦大学 制造2‑卤代烟腈的方法
US9664676B2 (en) 2013-09-06 2017-05-30 Cornell University RNA sequences that induce fluorescence of small molecule fluorophores
CN104370891B (zh) * 2014-10-17 2016-09-07 中国农业大学 一种5-(丁烯内酯-3-亚乙基)-2-氨基咪唑啉酮类化合物、制备方法及其应用
RU2730550C1 (ru) * 2019-05-15 2020-08-24 Федеральное государственное бюджетное образовательное учреждение высшего образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) Производное 2-селеноксо-тетрагидро-4н-имидазол-4-она, способ его получения и применения
WO2021114314A1 (en) * 2019-12-14 2021-06-17 Tongji University Novel heterocyclic derivatives with cardiomyocyte proliferation activity for treatment of heart diseases
US20220378748A1 (en) * 2019-12-14 2022-12-01 Shanghai East Hospital (East Hospital, Tongji University School Of Medicine) Use of Heterocyclic Derivatives with Cardiomyocyte Proliferation Activity for Treatment of Heart Diseases
WO2021133037A1 (ko) * 2019-12-26 2021-07-01 연세대학교 산학협력단 피롤리딘 유도체 및 이를 포함하는 베타-아밀로이드 또는 타우 단백질 관련 질병의 예방 또는 치료용 약학 조성물
EP3904354A1 (en) 2020-04-30 2021-11-03 Perha Pharmaceuticals New imidazolone derivatives as inhibitors of protein kinases in particular dyrk1a, clk1 and/or clk4
CN115515953A (zh) * 2020-04-30 2022-12-23 珀哈制药公司 作为蛋白激酶特别是dyrk1a、clk1和/或clk4的抑制剂的新的咪唑啉酮衍生物
EP4173674A1 (en) 2021-10-26 2023-05-03 Perha Pharmaceuticals Imidazolone derivatives as inhibitors of protein kinases in particular dyrk1a, clk1 and/or clk4
EP4173675A1 (en) 2021-10-26 2023-05-03 Perha Pharmaceuticals Imidazolone derivatives as inhibitors of protein kinases in particular dyrk1a, clk1 and/or clk4
EP4173673A1 (en) 2021-10-26 2023-05-03 Perha Pharmaceuticals Imidazolone derivatives as inhibitors of protein kinases in particular dyrk1a, clk1 and/or clk4
WO2025069008A1 (en) 2023-09-28 2025-04-03 Graviton Bioscience Bv Therapy for treating type 1 diabetes using rock2 and dyrk1 inhibitors

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1038050B (de) * 1955-11-17 1958-09-04 Farmaceutici Italia S A Soc Verfahren zur Herstellung von 5-(3', 4'-Dioxybenzyliden)-Derivaten heterocyclischer Verbindungen
US4431656A (en) * 1981-02-05 1984-02-14 Kanegafuchi Chemical Industry Company Limited 3,5-di-Tert-butylstyrene derivatives, salts thereof, and pharmaceutical compositions containing the same as an active ingredient
GR79384B (enExample) * 1982-08-20 1984-10-22 Hoechst Uk Ltd
IE940525L (en) * 1988-05-25 1989-11-25 Warner Lambert Co Known and selected novel arylmethylenyl derivatives of¹thiazolidinones, imidazolidinones and oxazolidinones useful¹as antiallergy agents and antiinflammatory agents
DE69007413T2 (de) * 1989-10-09 1994-07-21 Toshiba Kawasaki Kk Organisches Material für die nichtlineare Optik und nichtlineare optische Vorrichtung.
US5143928A (en) * 1990-03-27 1992-09-01 Warner-Lambert Company 3,5-di-tertiarybutyl-4-hydroxyphenylmethylene derivatives of 2-substituted thiazolidinones, oxazolidinones, and imidazolidinones as antiinflammatory agents
US5362733A (en) * 1990-04-27 1994-11-08 Orion-Yhtyma Oy Pharmacologically active catechol derivatives
JP3015702B2 (ja) * 1995-02-21 2000-03-06 株式会社アラクス イミダゾール誘導体及びそれらの薬剤として許容される酸付加塩及びその製造法並びにそれらを有効成分とする抗潰瘍剤
US6218437B1 (en) * 1996-09-30 2001-04-17 The Regents Of The University Of California Treatment and prevention of hepatic disorders
PL187019B1 (pl) * 1997-02-19 2004-04-30 Univ Jagiellonski Collegium Me Nowe związki, pochodne 5-arylideno-4-okso-2-imidazolidynoglicyny
EG21566A (en) * 1999-09-21 2001-12-31 Hosny Hamed Hoharam Synthesis of 5-(4-dimethylaminobenzli-dene)-2-phenylhydrozino (1,3-h) imidazole-4-one (iii)
JP2006510661A (ja) * 2002-12-06 2006-03-30 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー Ｐｉ３ｋの阻害剤としてのベンズオキサジン−３−オン類及びその誘導体
FR2855755B1 (fr) * 2003-06-05 2007-09-07 Oreal Utilisation d'au moins un filtre de la lumiere bleue pour preserve le capital de carotenoides endogenes de la peau; nouveaux filtres de la lumiere bleue; compositions cosmetiques
US8106214B2 (en) * 2003-07-28 2012-01-31 Merck Serono Sa 2-imino-4-(thio) oxo-5-polycyclovinylazolines for use as PI3 kinase inhibitors
EP1805174A1 (en) * 2004-10-14 2007-07-11 F.Hoffmann-La Roche Ag 1,5-naphthyridine azolidinones having cdk1 antiproliferative activity
US20090299063A1 (en) * 2005-03-29 2009-12-03 Paul Shapiro Inhibitors for Extracellular Signal-Regulated Kinase Docking Domains and Uses Therefor
US7304074B2 (en) * 2005-04-05 2007-12-04 Hoffmann-La Roche Inc. Substituted 1,5-naphthyridine azolinones
JP2007063444A (ja) * 2005-08-31 2007-03-15 Tdk Corp 錯化合物及びこれを用いた光記録媒体
US7371862B2 (en) * 2005-11-11 2008-05-13 Pfizer Italia S.R.L. Azaindolylidene derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
WO2007065261A1 (en) * 2005-12-07 2007-06-14 American Diagnostica Inc. Plasminogen activator inhibitor-1 inhibitors

Also Published As

Publication number Publication date
EP2185547A2 (fr) 2010-05-19
FR2919608B1 (fr) 2012-10-05
JP2010535180A (ja) 2010-11-18
US8563588B2 (en) 2013-10-22
WO2009050352A2 (fr) 2009-04-23
ES2644087T3 (es) 2017-11-27
EP2185547B1 (fr) 2017-07-19
FR2919608A1 (fr) 2009-02-06
WO2009050352A3 (fr) 2009-07-23
RU2491283C2 (ru) 2013-08-27
CN101784542A (zh) 2010-07-21
KR20100051698A (ko) 2010-05-17
US20100216855A1 (en) 2010-08-26
JP5926885B2 (ja) 2016-05-25
CN101784542B (zh) 2014-04-02
RU2010107262A (ru) 2011-09-10
CA2694377A1 (fr) 2009-04-23
MX2010001170A (es) 2010-06-25

Similar Documents

Publication Publication Date Title
BRPI0814457A2 (pt) Derivados de imidazolona, composições farmacêuticas, utilização de derivados de imidazolona, e, processo de síntese de derivados de imidazolona
EP2120573A4 (en) piperidine
DOP2007000084A (es) Derivados de dihidropirazolopirimidinona
ATE517621T1 (de) Verwendung von ampk-aktivierenden imidazol- derivaten, herstellungsverfahren dafür und diese enthaltende pharmazeutische zusammensetzungen
CR10562A (es) Nuevos derivados de piridazina
EP2200550A4 (en) TOPICAL GLYCOPYRROLATE FORMULATIONS
ZA201000912B (en) Novel 6-triazolopyridazinesulfanyl benzothiazole and benzimidazole derivatives,method for production thereof and application as medicaments and pharmaceutical compositions and novel use as met inhibitors
BRPI0906980A2 (pt) Composição de derivados e maleatados
LT2966175T (lt) Farmacinės kompozicijos turinčios korteksolono-17-alfa-propionato
BRPI0719955A2 (pt) Processo para síntese de derivados de fenóxi diaminopirimidina
IL199853A (en) Converged history of 5-Hydroxy-Admentil-2-Reindeer and Pharmaceutical Preparation containing them
EP2291078A4 (en) OXAZOLBENZIMIDAZOLDERIVATE
DK2303330T4 (da) Farmaceutiske sammensætninger til behandling af parkinsons sygdom
SMAP200900065A (it) Derivati ciclizzati come inibitori di eg-5
BRPI0814531A2 (pt) Processo de preparo de composições pulverulentas estáveis
EP2279532A4 (en) OXAZOLBENZIMIDAZOLDERIVATE
CR10809A (es) Derivados de heteroaril-pirrolidinil-y-piperidinil-cetona
BRPI0918206A2 (pt) derivados de animoéster e composição medicinal destes
DK2142533T3 (da) Imidazolidinonderivater
BR112012007869A2 (pt) "processo de síntese de um derivado de fórmula e composto"
ATE499367T1 (de) 1,3-dihydroimidazol-2-thionderivate als inhibitoren von dopamin-beta-hydroxylase
EP2041108A4 (en) 4-HYDROXYTHIOZENZAMIDE DERIVATIVES OF MEDICAMENTS
BRPI0817442A2 (pt) Formulações galênicas de composto orgânicos
SMT201400053B (it) Forme farmaceutiche orali di bendamustina
BRPI0809441A2 (pt) Formulação farmacêuticas de moléculas ghrh

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2385 DE 20-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.